Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 31 -40 of 88 Show results per page	View Search Criteria \| Help With Results

Last Modified: 11/1/1997 First Published: 11/1/1997


31.		Phase II Study of Doxorubicin Hydrochloride Liposome (Doxil) for Recurrent or Refractory Malignant Melanoma (Summary Last Modified 11/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				Not specified				Other				NBSG-9603 NCI-V97-1344

Last Modified: 9/1/2000 First Published: 6/1/1998


32.		Phase II Study of Doxorubicin HCl Liposome in Patients with Hepatobiliary Carcinoma (Summary Last Modified 09/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Other				BRUOG-HB-71 NCI-V98-1408, NCT00003296

Last Modified: 10/24/2007 First Published: 7/1/1998


33.		Phase II Study of Doxorubicin HCl Liposome and Paclitaxel for the Treatment of Endometrial Cancer, Tubal Cancers, and Sarcomas and Carcinosarcomas (Mixed Mesodermal Tumors) of Gynecologic Origin

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				Not specified				NCI				NYU-9708 NYGOG-NY9708, NCI-G98-1427, NCT00003334

Last Modified: 6/1/2002 First Published: 8/1/1998


34.		Phase II Study of Doxorubicin HCl Liposome, Cyclophosphamide, Vincristine, and Prednisone in Patients With AIDS-Related Systemic Lymphoma (Summary Last Modified 06/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				E-3D97 NCT00003388, E3D97

Last Modified: 8/1/2001 First Published: 11/1/1998


35.		Phase II Study of Doxorubicin HCl Liposome, Vincristine, and Dexamethasone in Newly Diagnosed and Previously Treated Patients with Multiple Myeloma (Summary Last Modified 08/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				Not specified				Pharmaceutical / Industry				CCF-IRB-2006 SEQUUS-CCF-IRB-2006, NCI-V98-1459, NCT00003493

Last Modified: 7/1/2000 First Published: 4/1/1999


36.		Phase II Study of Combination Cyclophosphamide, Doxorubicin HCl Liposome, Vincristine, and Prednisone in Elderly Patients with Newly Diagnosed Non-Hodgkin's Lymphoma (Summary Last Modified 07/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				60 and over				NCI, Pharmaceutical / Industry				CWRU-3498 SEQUUS-CWRU-3498, NCI-G99-1504

Last Modified: 5/22/2007 First Published: 7/1/1999


37.		Phase II Study of Paclitaxel, Cisplatin, and Doxorubicin HCl Liposome in Patients With Optimally Debulked Stage III Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				Not specified				NCI				SWOG-S9912 S9912, NCT00003896

Last Modified: 5/1/2000 First Published: 9/1/1999


38.		Phase II Study of Doxorubicin HCl Liposome in Patients With Hormone Refractory Prostate Cancer (Summary Last Modified 05/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				Not specified				NCI, Pharmaceutical / Industry				CWRU-NEO-1898 NEOPHARM-LED-P2, NCI-G99-1558, NCT00004014

Last Modified: 12/1/2000 First Published: 2/1/2000


39.		Phase II Study of Doxorubicin HCL Liposome in Patients With Advanced Gastric Adenocarcinoma (Summary Last Modified 12/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Other				LRI-IND.02-3/98 EU-99034, NCT00004236

Last Modified: 12/12/2007 First Published: 3/1/2000


40.		Phase II Study of Doxorubicin HCl Liposome and Docetaxel With or Without Trastuzumab (Herceptin™) in Women With Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				ECOG-3198 E3198, NCT00004888

Select All on One Page


					< Previous 1 2 3 4 5 6 7 Next >

| | | | | | | |

A Service of the National Cancer Institute